Mithramycin A is the only indication for testicular embryonic cell carcinoma, but because of its considerable toxicity and the availability of other effective drugs (such as cisplatin, bleomycin, vinblastine), it is currently the second choice for the treatment of testicular cancer. Others, such as glioma, metastatic brain cancer, malignant lymphoma, chorioepithelial cancer, breast cancer and so on, have certain curative effects.
Mithramycin A has a strong inhibitory effect on many animal tumors. Its mechanism is binding with DNA, inhibiting transcription and protein synthesis, inhibiting RNA synthesis, and acting on cell proliferation at all stages. It is the substrate of Pgp in MDR manifestation. Fluorescence staining of DNA was used in flow cytometry. Suitable for DNA detection.